Tempus AI (NASDAQ:TEM) CEO Sells 250,000 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 250,000 shares of the firm’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $42.06, for a total transaction of $10,515,000.00. Following the completion of the sale, the chief executive officer owned 200,000 shares of the company’s stock, valued at $8,412,000. The trade was a 55.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Up 6.6%

TEM traded up $2.74 during midday trading on Thursday, hitting $44.29. The company had a trading volume of 7,441,604 shares, compared to its average volume of 4,677,614. The stock’s 50 day moving average price is $51.45 and its 200 day moving average price is $52.77. Tempus AI, Inc. has a 52 week low of $40.77 and a 52 week high of $104.32. The company has a market capitalization of $7.95 billion, a price-to-earnings ratio of -25.75 and a beta of 3.46. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The company had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. During the same quarter in the prior year, the firm earned ($0.22) EPS. The business’s revenue was up 21.6% on a year-over-year basis. On average, research analysts anticipate that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tempus AI

A number of hedge funds have recently modified their holdings of the stock. Aberdeen Group plc raised its stake in Tempus AI by 64.2% in the 4th quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock valued at $15,530,000 after acquiring an additional 102,878 shares during the period. Pictet Asset Management Holding SA lifted its stake in Tempus AI by 291.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock worth $2,948,000 after purchasing an additional 36,096 shares in the last quarter. Bogart Wealth LLC raised its position in shares of Tempus AI by 365,087.5% in the fourth quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock worth $3,450,000 after buying an additional 58,414 shares in the last quarter. Eagle Health Investments LP bought a new position in Tempus AI in the 1st quarter worth about $11,588,000. Finally, Alethea Capital Management LLC purchased a new stake in shares of Tempus AI in the 4th quarter valued at about $1,863,000. Institutional investors own 24.22% of the company’s stock.

Wall Street Analysts Forecast Growth

TEM has been the topic of a number of research reports. Jefferies Financial Group initiated coverage on Tempus AI in a research report on Monday, April 13th. They set an “underperform” rating and a $35.00 target price on the stock. BTIG Research restated a “buy” rating and set a $80.00 price target on shares of Tempus AI in a research note on Monday, June 1st. Wolfe Research started coverage on shares of Tempus AI in a report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. HC Wainwright reissued a “buy” rating on shares of Tempus AI in a research note on Friday, July 24th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempus AI in a research report on Wednesday, June 17th. Nine equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $68.92.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Q2 results exceeded expectations. Tempus reported an adjusted loss of $0.04 per share, substantially narrower than the $0.14 analyst estimate and improved from a $0.22 loss a year earlier. Revenue rose 21.6% year over year to $382.49 million, slightly above the $379.69 million consensus. Tempus AI Q2 earnings report
• Positive Sentiment: Core diagnostics growth and AI investments supported the quarter. Management said investments in artificial intelligence are driving strong growth in the company’s two largest businesses, particularly Oncology Diagnostics. The company also cited progress in data and modeling capabilities, supporting its precision-medicine strategy. Tempus Reports Second Quarter 2026 Results
• Positive Sentiment: Full-year revenue guidance remained solid. Tempus maintained or updated 2026 revenue guidance at approximately $1.6 billion, broadly in line with Wall Street expectations. The guidance reinforces investor confidence in continued top-line expansion, although it does not represent a major upside surprise. Tempus AI earnings conference call

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.